NFRKB Antibody
Description
Introduction to NFRKB Antibody
The NFRKB antibody (e.g., Thermo Fisher Scientific’s A301-459A) is a polyclonal antibody developed to detect and study NFRKB, a 130 kDa protein encoded by the NFRKB gene (Entrez Gene ID: 4798; UniProt ID: Q6P4R8). This antibody is widely used in techniques such as Western blotting (WB), immunohistochemistry (IHC), and immunoprecipitation (IP) to investigate NFRKB’s role in transcriptional regulation, immune cell development, and cancer progression .
Target Protein Overview
NFRKB is a metazoan-specific subunit of the INO80 chromatin-remodeling complex. Key functions include:
-
Immune regulation: Binds variant NF-κB sites (e.g., in the IL-2Rα gene) and is critical for immune cell development .
-
Telomere maintenance: Protects alternative lengthening of telomeres (ALT) in cancer cells .
-
Cancer associations: Amplified in acute myeloid leukemia (AML) and linked to poor prognosis in hepatocellular carcinoma (HCC) .
Table 1: NFRKB Protein Characteristics
| Attribute | Detail |
|---|---|
| Gene Name | NFRKB (Nuclear Factor Related To Kappa-B-Binding Protein) |
| Molecular Weight | ~130 kDa |
| Complex Association | INO80 chromatin-remodeling complex subunit G (INO80G) |
| Key Domains | DNA-binding domain, nuclear localization signal |
| Cellular Localization | Nucleus (telomeres in ALT cells) |
Role in Immune System Development
NFRKB is essential for immune cell survival and differentiation:
-
AML amplification: Genomic amplification of NFRKB is observed in AML cases, correlating with dysregulated immune cell maturation .
-
Immunodeficiency link: Chromosomal deletions encompassing NFRKB are associated with combined cellular immunodeficiency .
Table 2: Key NFRKB Antibody Applications
| Application | Utility |
|---|---|
| Western Blot | Detects NFRKB in cell lysates (e.g., U2OS osteosarcoma cells) |
| Immunohistochemistry | Identifies nuclear NFRKB in HCC tumor tissues |
| Chromatin IP | Maps NFRKB binding sites at telomeres and NF-κB-regulated promoters |
Clinical Significance
-
Biomarker potential: High NFRKB expression in HCC is linked to advanced tumor stage and resistance to therapy .
-
Therapeutic target: Inhibiting NFRKB disrupts ALT in cancer cells, suggesting utility in telomere-targeted therapies .
Limitations and Future Directions
-
Specificity: Cross-reactivity with INO80 complex subunits requires validation via knockout controls.
-
Therapeutic challenges: NFRKB’s dual roles in immunity and cancer complicate targeted inhibition.
Product Specs
Target Background
- Research indicates that the DEUBAD domain within RPN13 (ADRM1) activates ubiquitin thioesterase L5 (UCH-L5), while the related DEUBAD domain in INO80G (NFRKB) inhibits UCH-L5. PMID: 25702870
- The structure of a novel helical domain of NFRKB has been determined at a resolution of 2.18 angstroms. PMID: 22984442
- NFRKB may play a role in the dysregulation of transcription frequently observed in minimal change nephrotic syndrome relapse. PMID: 22291976
